[{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.39000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VEL-101","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Asahi Kasei","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Asahi Kasei"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Xenikos B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ricin Toxin A Conjugated Monoclonal Antibodies","moa":"CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Veloxis Pharmaceuticals \/ Xenikos","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Xenikos"}]

Find Clinical Drug Pipeline Developments & Deals by Veloxis Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : T-Guard (ricin toxin A conjugated mAB) is designed to reset the body's immune system in life-threatening T cell‒mediated conditions, potentially including prevention of transplant-related rejection, treatment of acute solid-organ rejection, and severe ...

Brand Name : T-Guard

Molecule Type : Large molecule

Upfront Cash : Not Applicable

June 28, 2022

Lead Product(s) : Ricin Toxin A Conjugated Monoclonal Antibodies

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Xenikos B.V

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

Brand Name : VEL-101

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 18, 2022

Lead Product(s) : FR104

Therapeutic Area : Immunology

Highest Development Status : Phase I

Sponsor : OSE Immunotherapeutics SA

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

Brand Name : FR104

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 18, 2022

Lead Product(s) : VEL-101

Therapeutic Area : Immunology

Highest Development Status : Phase I

Sponsor : Asahi Kasei Pharma

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : The collaboration grants Veloxis worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. OSE Immunotherapeutics retains all rights to develop FR104 in autoimmune di...

Brand Name : FR104

Molecule Type : Large molecule

Upfront Cash : $8.5 million

April 26, 2021

Lead Product(s) : FR104

Therapeutic Area : Immunology

Highest Development Status : Phase I

Recipient : OSE Immunotherapeutics SA

Deal Size : $393.6 million

Deal Type : Collaboration

blank